Browse CA9

Summary
SymbolCA9
Namecarbonic anhydrase IX
Aliases CAIX; RCC-associated protein G250; CA-IX; P54/58N; RCC-associated antigen G250; carbonate dehydratase IX; me ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Nucleus, nucleolus Cell membrane Single-pass type I membrane protein Cell projection, microvillus membrane Single-pass type I membrane protein Note=Found on the surface microvilli and in the nucleus, particularly in nucleolus.
Domain PF00194 Eukaryotic-type carbonic anhydrase
Function

Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervical neoplasia.

> Gene Ontology
 
Biological Process GO:0001666 response to hypoxia
GO:0006730 one-carbon metabolic process
GO:0006820 anion transport
GO:0015701 bicarbonate transport
GO:0015711 organic anion transport
GO:0033574 response to testosterone
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0042493 response to drug
GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress
GO:0043620 regulation of DNA-templated transcription in response to stress
GO:0061418 regulation of transcription from RNA polymerase II promoter in response to hypoxia
GO:0070482 response to oxygen levels
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:1901654 response to ketone
Molecular Function GO:0004089 carbonate dehydratase activity
GO:0016829 lyase activity
GO:0016835 carbon-oxygen lyase activity
GO:0016836 hydro-lyase activity
Cellular Component GO:0005902 microvillus
GO:0016323 basolateral plasma membrane
GO:0031253 cell projection membrane
GO:0031528 microvillus membrane
GO:0098858 actin-based cell projection
> KEGG and Reactome Pathway
 
KEGG hsa00910 Nitrogen metabolism
Reactome R-HSA-2262749: Cellular response to hypoxia
R-HSA-2262752: Cellular responses to stress
R-HSA-1430728: Metabolism
R-HSA-1234174: Regulation of Hypoxia-inducible Factor (HIF) by oxygen
R-HSA-1234158: Regulation of gene expression by Hypoxia-inducible Factor
R-HSA-1475029: Reversible hydration of carbon dioxide
Summary
SymbolCA9
Namecarbonic anhydrase IX
Aliases CAIX; RCC-associated protein G250; CA-IX; P54/58N; RCC-associated antigen G250; carbonate dehydratase IX; me ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CA9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CA9 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26062742Renal Cell CarcinomaInhibit immunity (T cell function; infiltration)We show that anti-CAIX mAbs are capable of mediating human immune response in vivo including tumor infiltration of NK cells and activation of T cells, resulting in inhibition of CAIX(+) tumor growth.
19074859MelanomaPromote immunity (T cell function)In a murine melanoma model, a complex of CA9 and gp100 generated a gp100-specific antitumor response. A soluble form of CA9 shed from tumor cells had the same chaperone-like functions, providing renal tumors and hypoxic cells with a mechanism for stimulating an immune response against extracellular antigens. Interleukin-2 treatment of patient renal tumors in short-term culture increased CA9 shedding, suggesting a strategy for augmenting the immunogenicity of renal tumors.
16931630leukemiaPromote immunitySpecific T-cell responses were detected in 8 (47%) of 17 patients with AML in complete remission for RHAMM/HMMR-R3 peptide, in 7 (70%) of 10 for PRAME-P3 peptide, and in 6 (60%) of 10 for newly characterized G250/CA9-G2 peptide, a significant increased immune response compared with patients with AML patients who had refractory disease. In conclusion, expression of the TAAs RHAMM/HMMR, PRAME, and G250/CA9 can induce strong antileukemic immune responses, possibly enabling MRD control.
Summary
SymbolCA9
Namecarbonic anhydrase IX
Aliases CAIX; RCC-associated protein G250; CA-IX; P54/58N; RCC-associated antigen G250; carbonate dehydratase IX; me ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CA9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.54 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCA9
Namecarbonic anhydrase IX
Aliases CAIX; RCC-associated protein G250; CA-IX; P54/58N; RCC-associated antigen G250; carbonate dehydratase IX; me ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CA9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6620.177
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2960.102
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1980.775
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9120.0996
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1120.473
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6620.716
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3770.667
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.70.608
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0030.999
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1050.627
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7310.62
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6360.137
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CA9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCA9
Namecarbonic anhydrase IX
Aliases CAIX; RCC-associated protein G250; CA-IX; P54/58N; RCC-associated antigen G250; carbonate dehydratase IX; me ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CA9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCA9
Namecarbonic anhydrase IX
Aliases CAIX; RCC-associated protein G250; CA-IX; P54/58N; RCC-associated antigen G250; carbonate dehydratase IX; me ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CA9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CA9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCA9
Namecarbonic anhydrase IX
Aliases CAIX; RCC-associated protein G250; CA-IX; P54/58N; RCC-associated antigen G250; carbonate dehydratase IX; me ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CA9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCA9
Namecarbonic anhydrase IX
Aliases CAIX; RCC-associated protein G250; CA-IX; P54/58N; RCC-associated antigen G250; carbonate dehydratase IX; me ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CA9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCA9
Namecarbonic anhydrase IX
Aliases CAIX; RCC-associated protein G250; CA-IX; P54/58N; RCC-associated antigen G250; carbonate dehydratase IX; me ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CA9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCA9
Namecarbonic anhydrase IX
Aliases CAIX; RCC-associated protein G250; CA-IX; P54/58N; RCC-associated antigen G250; carbonate dehydratase IX; me ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CA9 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CA9.
ID Name Drug Type Targets #Targets
DB00562BenzthiazideSmall MoleculeCA1, CA12, CA2, CA4, CA9, SLC12A36
DB00774HydroflumethiazideSmall MoleculeATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A18
DB00909ZonisamideSmall MoleculeCA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, ......31
DB00999HydrochlorothiazideSmall MoleculeCA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A37
DB05304WX-G250Small MoleculeCA9, IL22
DB08846Ellagic AcidSmall MoleculeCA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1 ......17
DB09460Sodium carbonateSmall MoleculeCA1, CA2, CA4, CA94